Yuqiang Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Yuqiang Wang has a total of 88 co-authors. Here are the top co-authors by number of shared publications:
Pei Yu
Institute of New Drug Research and Guangzhou Key Laboratory of Innovative Chemical Drug Research in Cardio-cerebrovascular Diseases, Jinan University College of Pharmacy, Guangzhou, 510632, China
7 shared publicationsZaijun Zhang
Institute of New Drug Research and Guangzhou Key Laboratory of Innovative Chemical Drug Research in Cardio-cerebrovascular Diseases, Jinan University College of Pharmacy, Guangzhou, 510632, China
5 shared publicationsGaoxiao Zhang
Institute of New Drug Research and Guangzhou Key Laboratory of Innovative Chemical Drug Research in Cardio-cerebrovascular Diseases, Jinan University College of Pharmacy, Guangzhou, 510632, China
3 shared publications- Jie Jiang
Institute of New Drug Research, College of Pharmacy, Jinan University, Guangzhou, The People’s Republic of China
3 shared publications Yewei Sun
Institute of New Drug Research and Guangzhou Key Laboratory of Innovative Chemical Drug Research in Cardio-cerebrovascular Diseases, Jinan University College of Pharmacy, Guangzhou, 510632, China
3 shared publications- Zaijun Zhang
State Key Laboratory of Bioactive Molecules and Druggability Assessment, and Guangzhou Key Laboratory of Innovative Chemical Drug Research in Cardio-cerebrovascular Diseases, and Institute of New Drug Research, Jinan University, Guangzhou, China
3 shared publications
Latest Publications
- Open Access
- 14 November 2016
- Published by Springer Nature in Scientific Reports
- Vol. 6 (1) , 37148
Tetramethylpyrazine nitrone, a multifunctional neuroprotective agent for ischemic stroke therapy
TBN, a novel tetramethylpyrazine derivative armed with a powerful free radical-scavenging nitrone moiety, has been reported to reduce cerebral infarction in rats through multi-functional mechanisms of action. Here we study the therapeutic effects of TBN on non-human primate model of stroke. Thirty male Cynomolgus macaques were subjected to stroke with 4 hours ischemia and then reperfusion. TBN were injected intravenously at 3 or 6 hours after the onset of ischemia. Cerebral infarction was examined by magnetic resonance imaging at 1 and 4 weeks post ischemia. Neurological severity scores were evaluated during 4 weeks observation. At the end of experiment, protein markers associated with the stroke injury and TBN treatment were screened by quantitative proteomics. We found that TBN readily penetrated the blood brain barrier and reached effective therapeutic concentration after intravenous administration. It significantly reduced brain infarction and modestly preserved the neurological function of stroke-affected arm. TBN suppressed over-expression of neuroinflammatory marker vimentin and decreased the numbers of GFAP-positive cells, while reversed down-regulation of myelination-associated protein 2′, 3′-cyclic-nucleotide 3′-phosphodiesterase and increased the numbers of NeuN-positive cells in the ipsilateral peri-infarct area. TBN may serve as a promising new clinical candidate for the treatment of ischemic stroke.
- 14 November 2016
- Published by Springer Nature in Scientific Reports
- Vol. 6 (1) , 37148
Open AccessTetramethylpyrazine nitrone, a multifunctional neuroprotective agent for ischemic stroke therapy
TBN, a novel tetramethylpyrazine derivative armed with a powerful free radical-scavenging nitrone moiety, has been reported to reduce cerebral infarction in rats through multi-functional mechanisms of action. Here we study the therapeutic effects of TBN on non-human primate model of stroke. Thirty male Cynomolgus macaques were subjected to stroke with 4 hours ischemia and then reperfusion. TBN were injected intravenously at 3 or 6 hours after the onset of ischemia. Cerebral infarction was examined by magnetic resonance imaging at 1 and 4 weeks post ischemia. Neurological severity scores were evaluated during 4 weeks observation. At the end of experiment, protein markers associated with the stroke injury and TBN treatment were screened by quantitative proteomics. We found that TBN readily penetrated the blood brain barrier and reached effective therapeutic concentration after intravenous administration. It significantly reduced brain infarction and modestly preserved the neurological function of stroke-affected arm. TBN suppressed over-expression of neuroinflammatory marker vimentin and decreased the numbers of GFAP-positive cells, while reversed down-regulation of myelination-associated protein 2′, 3′-cyclic-nucleotide 3′-phosphodiesterase and increased the numbers of NeuN-positive cells in the ipsilateral peri-infarct area. TBN may serve as a promising new clinical candidate for the treatment of ischemic stroke.
- 8 June 2016
- Published by Springer Nature in NeuroMolecular Medicine
- Vol. 18 (4) , 561-572
Potent Protection Against MPP+-Induced Neurotoxicity via Activating Transcription Factor MEF2D by a Novel Derivative of Naturally Occurring Danshensu/Tetramethylpyrazine
Danshensu (DSS) and tetramethylpyrazine (TMP) are active ingredients of Salvia miltiorrhiza Bge. and Ligusticum chuanxiong Hort that are widely used in oriental medicine. Structural combination of compounds with known biological activity may lead to the formation of a molecule with multiple properties or new function profile. In the current study, the neuroprotective effects of DT-010, a novel analogue in which TMP was coupled to DSS through an ester bond and two allyl groups at the carboxyl group, were evaluated in a cellular model of Parkinson’s disease (PD). As evidenced by the increase in cell survival, as well as the decrease in the number of Hoechst-stained apoptotic nuclei and the level of intracellular accumulation of reactive oxygen species, DT-010 at 3–30 µM substantially protected against MPP+-induced neurotoxicity in both PC12 cells and primary cerebellar granule neurons, a protection that was more potent and efficacious than its parent molecules DSS and TMP. Very encouragingly, we found that DT-010, but not DSS or TMP, could enhance myocyte enhancer factor 2D (MEF2D) transcriptional activity using luciferase reporter gene assay. The neuroprotective effects of DT-010 could be blocked by pharmacologic inhibition of PI3K pathways with LY294002, or MEF2D pathway with short hairpin RNA-mediated knockdown of MEF2D. Furthermore, western blot analysis revealed that DT-010 potentiates Akt protein expression against MPP+ to down-regulate MEF2D inhibitor GSK3β. Taken together, the results suggest that DT-010 prevents MPP+-induced neurotoxicity via enhancing MEF2D through the activation of PI3K/Akt/GSK3β pathway. DT-010 may be a potential candidate for further preclinical study for preventing and treating PD. Graphical Abstract
- 8 June 2016
- Published by Springer Nature in NeuroMolecular Medicine
- Vol. 18 (4) , 561-572
Potent Protection Against MPP+-Induced Neurotoxicity via Activating Transcription Factor MEF2D by a Novel Derivative of Naturally Occurring Danshensu/Tetramethylpyrazine
Danshensu (DSS) and tetramethylpyrazine (TMP) are active ingredients of Salvia miltiorrhiza Bge. and Ligusticum chuanxiong Hort that are widely used in oriental medicine. Structural combination of compounds with known biological activity may lead to the formation of a molecule with multiple properties or new function profile. In the current study, the neuroprotective effects of DT-010, a novel analogue in which TMP was coupled to DSS through an ester bond and two allyl groups at the carboxyl group, were evaluated in a cellular model of Parkinson’s disease (PD). As evidenced by the increase in cell survival, as well as the decrease in the number of Hoechst-stained apoptotic nuclei and the level of intracellular accumulation of reactive oxygen species, DT-010 at 3–30 µM substantially protected against MPP+-induced neurotoxicity in both PC12 cells and primary cerebellar granule neurons, a protection that was more potent and efficacious than its parent molecules DSS and TMP. Very encouragingly, we found that DT-010, but not DSS or TMP, could enhance myocyte enhancer factor 2D (MEF2D) transcriptional activity using luciferase reporter gene assay. The neuroprotective effects of DT-010 could be blocked by pharmacologic inhibition of PI3K pathways with LY294002, or MEF2D pathway with short hairpin RNA-mediated knockdown of MEF2D. Furthermore, western blot analysis revealed that DT-010 potentiates Akt protein expression against MPP+ to down-regulate MEF2D inhibitor GSK3β. Taken together, the results suggest that DT-010 prevents MPP+-induced neurotoxicity via enhancing MEF2D through the activation of PI3K/Akt/GSK3β pathway. DT-010 may be a potential candidate for further preclinical study for preventing and treating PD. Graphical Abstract
- Open Access
- 1 January 2016
- Published by Asian Publication Corporation in Asian Journal of Chemistry
- Vol. 28 (11) , 2555-2561
Design, Synthesis and Biological Evaluations of Novel Conjugates of Danshensu, Tetramethylpyrazine and Hydrogen Sulfide Donors as Cardioprotective Agents
- 1 January 2016
- Published by Asian Publication Corporation in Asian Journal of Chemistry
- Vol. 28 (11) , 2555-2561
Open AccessDesign, Synthesis and Biological Evaluations of Novel Conjugates of Danshensu, Tetramethylpyrazine and Hydrogen Sulfide Donors as Cardioprotective Agents
- 1 January 2016
- Published by Asian Publication Corporation in Asian Journal of Chemistry
- Vol. 28 (9) , 2085-2088
Synthesis and Biological Evaluation of Tetramethylpyrazine Nitrates as Potential Anti-ischemic Stroke Agent
- 1 January 2016
- Published by Asian Publication Corporation in Asian Journal of Chemistry
- Vol. 28 (9) , 2085-2088
Synthesis and Biological Evaluation of Tetramethylpyrazine Nitrates as Potential Anti-ischemic Stroke Agent
- 1 January 2015
- Published by Asian Publication Corporation in Asian Journal of Chemistry
- Vol. 27 (7) , 2545-2547
Synthesis of 3-(5H-Pyrazolyl)cyclobutanone Derivatives
- 1 January 2015
- Published by Asian Publication Corporation in Asian Journal of Chemistry
- Vol. 27 (7) , 2545-2547
Synthesis of 3-(5H-Pyrazolyl)cyclobutanone Derivatives
- 1 January 2014
- Published by Shanghai Institute of Organic Chemistry in Chinese Journal of Organic Chemistry
- Vol. 34 (6) , 1227
A SelectiveO- andN-Acylation Protocol for Carbamyl Chloride
- 1 January 2014
- Published by Shanghai Institute of Organic Chemistry in Chinese Journal of Organic Chemistry
- Vol. 34 (6) , 1227
A SelectiveO- andN-Acylation Protocol for Carbamyl Chloride
- Open Access
- 1 December 2012
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 56 (12) , 6088-6094
Effects of 14-Alpha-Lipoyl Andrographolide on Quorum Sensing in Pseudomonas aeruginosa
InPseudomonas aeruginosa, the quorum-sensing (QS) system is closely related to biofilm formation. We previously demonstrated that 14-alpha-lipoyl andrographolide (AL-1) has synergistic effects on antibiofilm and antivirulence factors (pyocyanin and exopolysaccharide) ofP. aeruginosawhen combined with conventional antibiotics, while it has little inhibitory effect on its growth. However, its molecular mechanism remains elusive. Here we investigated the effect of AL-1 on QS systems, especially the Las and Rhl systems. This investigation showed that AL-1 can inhibit LasR–3-oxo-C12-homoserine lactone (HSL) interactions and repress the transcriptional level of QS-regulated genes. Reverse transcription (RT)-PCR data showed that AL-1 significantly reduced the expression levels oflasR,lasI,rhlR, andrhlIin a dose-dependent manner. AL-1 not only decreased the expression level of Psl, which is positively regulated by the Las system, but also increased the level of secretion of ExoS, which is negatively regulated by the Rhl system, indicating that AL-1 has multiple effects on both the Las and Rhl systems. It is no wonder that AL-1 showed synergistic effects with other antimicrobial agents in the treatment ofP. aeruginosainfections.
- 1 December 2012
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 56 (12) , 6088-6094
Open AccessEffects of 14-Alpha-Lipoyl Andrographolide on Quorum Sensing in Pseudomonas aeruginosa
InPseudomonas aeruginosa, the quorum-sensing (QS) system is closely related to biofilm formation. We previously demonstrated that 14-alpha-lipoyl andrographolide (AL-1) has synergistic effects on antibiofilm and antivirulence factors (pyocyanin and exopolysaccharide) ofP. aeruginosawhen combined with conventional antibiotics, while it has little inhibitory effect on its growth. However, its molecular mechanism remains elusive. Here we investigated the effect of AL-1 on QS systems, especially the Las and Rhl systems. This investigation showed that AL-1 can inhibit LasR–3-oxo-C12-homoserine lactone (HSL) interactions and repress the transcriptional level of QS-regulated genes. Reverse transcription (RT)-PCR data showed that AL-1 significantly reduced the expression levels oflasR,lasI,rhlR, andrhlIin a dose-dependent manner. AL-1 not only decreased the expression level of Psl, which is positively regulated by the Las system, but also increased the level of secretion of ExoS, which is negatively regulated by the Rhl system, indicating that AL-1 has multiple effects on both the Las and Rhl systems. It is no wonder that AL-1 showed synergistic effects with other antimicrobial agents in the treatment ofP. aeruginosainfections.
- 19 March 2012
- Published by Wiley in Journal of Neuroscience Research
- Vol. 90 (8) , 1662-1669
Therapeutic effects of tetramethylpyrazine nitrone in rat ischemic stroke models
Free radical-mediated neuronal cell damage is an important pathological process in ischemic stroke. We have previously reported a novel dual-functional agent, 2-[[(1,1-dimethylethyl)oxidoimino]-methyl]-3,5,6-trimethylpyrazine (TBN), a derivative of tetramethylpyrazine armed with anitrone moiety. In this report, we further evaluate TBN'stherapeutic parameters in a rat middle cerebral artery occlusion (MCAO) model. Its abilities to cross the blood–brain barrier, scavenge free radicals, and inhibitCa2+ influx were also investigated. TBN showed significant activity in both the transient MCAO (t-MCAO) and permanent MCAO (p-MCAO) stroke models in the rat. The therapeutic time window is 8 hr in the t-MCAO model. TBN readily crossed the blood–brain barrier and in vitro had strong activity in neutralizing ·OH, O− 2·, and ONOO− and significantly decreased intracellular Ca2+concentration. TBN is a promising new treatment forischemic stroke, with multiple mechanisms of action. It blocks Ca2+ overload and neutralizes ·OH, O−2·, and ONOO−.
- 19 March 2012
- Published by Wiley in Journal of Neuroscience Research
- Vol. 90 (8) , 1662-1669
Therapeutic effects of tetramethylpyrazine nitrone in rat ischemic stroke models
Free radical-mediated neuronal cell damage is an important pathological process in ischemic stroke. We have previously reported a novel dual-functional agent, 2-[[(1,1-dimethylethyl)oxidoimino]-methyl]-3,5,6-trimethylpyrazine (TBN), a derivative of tetramethylpyrazine armed with anitrone moiety. In this report, we further evaluate TBN'stherapeutic parameters in a rat middle cerebral artery occlusion (MCAO) model. Its abilities to cross the blood–brain barrier, scavenge free radicals, and inhibitCa2+ influx were also investigated. TBN showed significant activity in both the transient MCAO (t-MCAO) and permanent MCAO (p-MCAO) stroke models in the rat. The therapeutic time window is 8 hr in the t-MCAO model. TBN readily crossed the blood–brain barrier and in vitro had strong activity in neutralizing ·OH, O− 2·, and ONOO− and significantly decreased intracellular Ca2+concentration. TBN is a promising new treatment forischemic stroke, with multiple mechanisms of action. It blocks Ca2+ overload and neutralizes ·OH, O−2·, and ONOO−.
- Open Access
- 1 January 2012
- Published by Pharmaceutical Society of Japan in Biological and Pharmaceutical Bulletin
- Vol. 35 (8) , 1295-1299
Synthesis and Preliminary Anticancer Evaluation of 10-Hydroxycamptothecin Analogs
We have synthesized new 10-hydroxycamptothecin (HCPT) analogs and evaluated their anticancer activity in cell culture and in experimental animal tumor model. Although the new analogs were less potent against L1210 leukemia cells in vitro, some of them were more efficacious against L1210 leukemia in vivo compared to the parent HCPT.
- 1 January 2012
- Published by Pharmaceutical Society of Japan in Biological and Pharmaceutical Bulletin
- Vol. 35 (8) , 1295-1299
Open AccessSynthesis and Preliminary Anticancer Evaluation of 10-Hydroxycamptothecin Analogs
We have synthesized new 10-hydroxycamptothecin (HCPT) analogs and evaluated their anticancer activity in cell culture and in experimental animal tumor model. Although the new analogs were less potent against L1210 leukemia cells in vitro, some of them were more efficacious against L1210 leukemia in vivo compared to the parent HCPT.
- 1 August 2011
- Vol. 46 (8) , 1015-8
Synthesis and preliminary evaluation of anti-HIV agent AZT prodrug.
In this research, phosphate and thiophosphate prodrugs 3a, 3b of anti-HIV agent AZT were synthesized, and their anti-HIV activities and cytotoxicities were investigated in vitro. Results showed that the prodrugs 3a and 3b with an IC50 value of 11.0 and 4.0 micromol x L(-1), respectively, were less toxic than AZT (1.0 micromol x L(-1)). Although the EC50 values of both 3a (0.04 micromol x (L(-1) and 3b (0.16 micromol x L(-1)) were lower than that of AZT (0.01 micromol x L(-1)), the therapeutic index (IC50/EC50) of prodrug 3a (275) was much higher than that of both AZT (100) and prodrug 3b (25). This indicated that the prodrug 3a merited further investigation as an anti-HIV agent.
- 1 August 2011
- Vol. 46 (8) , 1015-8
Synthesis and preliminary evaluation of anti-HIV agent AZT prodrug.
In this research, phosphate and thiophosphate prodrugs 3a, 3b of anti-HIV agent AZT were synthesized, and their anti-HIV activities and cytotoxicities were investigated in vitro. Results showed that the prodrugs 3a and 3b with an IC50 value of 11.0 and 4.0 micromol x L(-1), respectively, were less toxic than AZT (1.0 micromol x L(-1)). Although the EC50 values of both 3a (0.04 micromol x (L(-1) and 3b (0.16 micromol x L(-1)) were lower than that of AZT (0.01 micromol x L(-1)), the therapeutic index (IC50/EC50) of prodrug 3a (275) was much higher than that of both AZT (100) and prodrug 3b (25). This indicated that the prodrug 3a merited further investigation as an anti-HIV agent.